Soligenix Advances HyBryte as Potential First-Line CTCL Treatment with Promising FLASH Results

Soligenix Inc. continues to build momentum in the treatment of early-stage cutaneous T-cell lymphoma through promising results from its pivotal FLASH trial and ongoing FLASH 2 confirmatory study. HyBryte, a novel non-UV light-activated therapy using synthetic hypericin, has demonstrated statistically significant efficacy and safety, offering hope in a field where therapeutic innovation has lagged. The treatment represents a significant advancement for patients with this rare form of lymphoma who have limited treatment options available.

In the original FLASH study, nearly half of patients showed meaningful response at 18 weeks, while interim results from an independent University of Pennsylvania study reported an even more impressive 75% response rate. These results suggest that HyBryte could provide substantial clinical benefit for patients suffering from early-stage CTCL. The FLASH 2 study builds on these findings with an improved design while addressing regulatory requirements for confirmatory evidence needed for potential drug approval.

The significance of these developments extends beyond the immediate clinical benefits. If successful, HyBryte could become the first approved front-line therapy for early-stage CTCL, potentially reshaping standards of care and strengthening Soligenix's position as a leader in rare dermatologic oncology. This represents a major milestone in the treatment landscape for CTCL patients who currently lack standardized first-line treatment options. The company's progress can be followed through their corporate communications available at https://ibn.fm/SNGX.

Beyond the CTCL program, Soligenix's broader development pipeline includes expansion of synthetic hypericin into psoriasis treatment and several vaccine programs targeting various infectious diseases. The company's Public Health Solutions business segment has been supported with government grants and contract funding from several federal agencies, including the National Institute of Allergy and Infectious Diseases. Additional information about the company's research and development activities is accessible at https://www.Soligenix.com.

The ongoing FLASH 2 study represents a critical step toward potential regulatory approval and commercialization of HyBryte worldwide. Success in this confirmatory trial could establish a new standard of care for early-stage CTCL patients, addressing a significant unmet medical need in the rare disease community. The promising results to date suggest that HyBryte may offer a safe and effective alternative to existing treatments, potentially transforming the therapeutic approach to this challenging condition.